article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

But not everyone in drug development is playing this game. So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation? No wonder investing in drug development is so hard! But how do you know which game you are playing?

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Key Challenges of Specialty Pharma Drug Development Project Management

thought leadership

Specialty pharma companies are focused on developing drugs for niche markets, such as rare diseases , cancer, and other complex conditions. These drugs often require significant investment in research and development, and their development requires careful project management.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Focus on core competencies : By outsourcing trial management to CROs, pharmaceutical companies and research institutions can concentrate on drug development and scientific innovation, rather than administrative tasks. Their ability to adapt to evolving regulations and industry standards reduces the likelihood of costly setbacks.

article thumbnail

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

Generic drugs are also an interesting case and are common targets for repurposing due to their established safety profiles and long market presence. They also provide a level playing field for academics, biotech companies, and pharma giants to compete on.

Drugs 98
article thumbnail

#Unshackled: The evolving definition of asset-centricity

DrugBaron

Buoyed by the string of successes in early discovery delivered by this approach, attention inevitably turned to how we might leverage the same insights to improve return on capital in the rest of the long path through drug development. In practice, this looks much more like a traditional pharma company than a biotech.